APA (7th ed.) Citation

Riek, M., Scherer, A., Möller, B., Ciurea, A., von Mühlenen, I., Gabay, C., . . . Finckh, A. (2023). Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Scientific Reports, 13(1), 1. https://doi.org/10.1038/s41598-023-44841-w

Chicago Style (17th ed.) Citation

Riek, Myriam, et al. "Serious Infection Risk of Tofacitinib Compared to Biologics in Patients with Rheumatoid Arthritis Treated in Routine Clinical Care." Scientific Reports 13, no. 1 (2023): 1. https://doi.org/10.1038/s41598-023-44841-w.

MLA (9th ed.) Citation

Riek, Myriam, et al. "Serious Infection Risk of Tofacitinib Compared to Biologics in Patients with Rheumatoid Arthritis Treated in Routine Clinical Care." Scientific Reports, vol. 13, no. 1, 2023, p. 1, https://doi.org/10.1038/s41598-023-44841-w.